Journal of Clinical Oncology, Vol 16, 3641-3648, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study

MB Harris, P Gieser, AM Goorin, A Ayala, SJ Shochat, WS Ferguson, T Holbrook and MP Link
Tomorrow's Children's Institute, Hackensack University Medical Center, NJ, USA. wendyb@nwu.edu

PURPOSE: To estimate the duration of survival (S) of patients with metastatic osteosarcoma (MOS) at diagnosis treated with a multiagent, ifosfamide-containing chemotherapeutic and surgical regimen and to evaluate the toxicity of this regimen. PATIENTS AND METHODS: Thirty patients aged younger than 30 years received two courses of ifosfamide followed by surgery on the primary tumor and metastatic sites. Patients then received a postsurgical multiagent chemotherapeutic regimen that consisted of high-dose methotrexate (HDMTX), ifosfamide, doxorubicin, and cisplatin. RESULTS: The 5-year event-free survival (EFS) rate was 46.7% (95% confidence interval [CI]; 28.5 to 64.9) and 5-year S rate was 53.3% (95% CI; 35.1 to 71.5). Three patients with bone metastases and one patient with lymph node metastases died. Twenty-six patients presented with pulmonary metastatic nodules only. Eight of these patients had at least eight nodules at diagnosis and had an estimated 5- year EFS rate of 25.0% compared with 66.7% for the 18 patients with less than eight nodules (P=.06). Fourteen patients presented with bilateral lung metastases and had a 5-year EFS rate of 35.7% compared with the 12 patients who presented with unilateral involvement and had a 5-year EFS rate of 75.0% (P=.03). The hematopoietic toxicity experienced by the patients during the entire regimen was relatively mild. Seven patients had renal toxicity characterized by hypophosphatemia and/or hypokalemia. CONCLUSION: This ifosfamide- containing regimen is tolerable and effective in the treatment of patients with osteosarcoma (OS) who present with lung metastases. However, better regimens are required for this group of patients.

This article has been cited by other articles:

				I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128. [Abstract] [Full Text] [PDF]

				R. K. Heck Jr., T. D. Peabody, and M. A. Simon Staging of Primary Malignancies of Bone CA Cancer J Clin, November 1, 2006; 56(6): 366 - 375. [Abstract] [Full Text] [PDF]

				G. Bacci, N. Fabbri, A. Balladelli, C. Forni, E. Palmerini, and P. Picci Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients J Bone Joint Surg Br, August 1, 2006; 88-B(8): 1071 - 1075. [Abstract] [Full Text] [PDF]

				L. Kager, A. Zoubek, U. Kastner, B. Kempf-Bielack, J. Potratz, R. Kotz, G. U. Exner, C. Franzius, S. Lang, R. Maas, et al. Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group J. Clin. Oncol., April 1, 2006; 24(10): 1535 - 1541. [Abstract] [Full Text] [PDF]

				R. J. Weil, R. R. Lonser, and M. M. Quezado CNS Manifestations of Malignancies: CASE 2. Skull and Brain Metastasis From Tibial Osteosarcoma J. Clin. Oncol., June 20, 2005; 23(18): 4226 - 4229. [Full Text] [PDF]

				R. P. Sanders, R. Drissi, C. A. Billups, N. C. Daw, M. B. Valentine, and J. S. Dome Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma J. Clin. Oncol., September 15, 2004; 22(18): 3790 - 3797. [Abstract] [Full Text] [PDF]

				N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]

				G. Bacci, A. Briccoli, M. Rocca, S. Ferrari, D. Donati, A. Longhi, F. Bertoni, P. Bacchini, S. Giacomini, C. Forni, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide Ann. Onc., July 1, 2003; 14(7): 1126 - 1134. [Abstract] [Full Text] [PDF]

				L. Kager, A. Zoubek, U. Potschger, U. Kastner, S. Flege, B. Kempf-Bielack, D. Branscheid, R. Kotz, M. Salzer-Kuntschik, W. Winkelmann, et al. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols J. Clin. Oncol., May 15, 2003; 21(10): 2011 - 2018. [Abstract] [Full Text] [PDF]

				K. Scotlandi, S. Perdichizzi, M. C. Manara, M. Serra, S. Benini, V. Cerisano, R. Strammiello, M. Mercuri, G. Reverter-Branchat, G. Faircloth, et al. Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells Clin. Cancer Res., December 1, 2002; 8(12): 3893 - 3903. [Abstract] [Full Text] [PDF]

				C. Khanna, J. Prehn, D. Hayden, R. D. Cassaday, J. Caylor, S. Jacob, S. M. Bose, S.-H. Hong, S. M. Hewitt, and L. J. Helman A Randomized Controlled Trial of Octreotide Pamoate Long-acting Release and Carboplatin versus Carboplatin Alone in Dogs with Naturally Occurring Osteosarcoma: Evaluation of Insulin-like Growth Factor Suppression and Chemotherapy Clin. Cancer Res., July 1, 2002; 8(7): 2406 - 2412. [Abstract] [Full Text] [PDF]

				A. M. Goorin, M. B. Harris, M. Bernstein, W. Ferguson, M. Devidas, G. P. Siegal, M. C. Gebhardt, C. L. Schwartz, M. Link, and H. E. Grier Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial J. Clin. Oncol., January 15, 2002; 20(2): 426 - 433. [Abstract] [Full Text] [PDF]

				W. H. Meyer, C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial J. Clin. Oncol., January 1, 2001; 19(1): 171 - 182. [Abstract] [Full Text] [PDF]

				R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey, and P. A. Meyers Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma J. Clin. Oncol., September 1, 1999; 17(9): 2781 - 2781. [Abstract] [Full Text] [PDF]

				C. A.S. Arndt and W. M. Crist Common Musculoskeletal Tumors of Childhood and Adolescence N. Engl. J. Med., July 29, 1999; 341(5): 342 - 352. [Full Text] [PDF]